Last reviewed · How we verify
GSK's investigational vaccine 692342
GSK's investigational vaccine 692342 is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development.
At a glance
| Generic name | GSK's investigational vaccine 692342 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants (PHASE2)
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults (PHASE2)
- Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease (PHASE2)
- Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK's investigational vaccine 692342 CI brief — competitive landscape report
- GSK's investigational vaccine 692342 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK's investigational vaccine 692342
What is GSK's investigational vaccine 692342?
GSK's investigational vaccine 692342 is a Biologic drug developed by GlaxoSmithKline.
Who makes GSK's investigational vaccine 692342?
GSK's investigational vaccine 692342 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is GSK's investigational vaccine 692342 in?
GSK's investigational vaccine 692342 is in Phase 2.